Literature DB >> 25719388

Epigenetic biomarkers in the blood of patients with urological malignancies.

Jörg Ellinger1, Stefan C Müller, Dimo Dietrich.   

Abstract

In the era of personalized medicine, there is an urgent need for non-invasive biomarkers to optimize the individual treatment of cancer patients. Epigenetic alterations, including DNA methylation and non-coding RNAs, are a hallmark of malignant tumors. The detection of many of these epigenetic conditions is feasible in bodily fluids, that is, blood plasma and serum, and may therefore be used for liquid biopsy. In this review, we summarize and discuss the current state of research on circulating epigenetic alterations (DNA methylation, miRNA and long non-coding RNA) in serum and plasma of patients with bladder cancer, prostate cancer, renal cell carcinoma and testicular germ cell cancer.

Entities:  

Keywords:  DNA methylation; biomarker; bladder cancer; body fluids; liquid biopsy; lncRNA; miRNA; prostate cancer; renal cell carcinoma; testicular cancer

Mesh：

Substances：

Year:  2015        PMID： 25719388     DOI： 10.1586/14737159.2015.1019477

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN： 1473-7159            Impact factor:   5.225


  29 in total

1.  YRNA expression in prostate cancer patients: diagnostic and prognostic implications.

Authors:  Yuri Tolkach; Eva-Maria Niehoff; Anna Franziska Stahl; Chenming Zhao; Glen Kristiansen; Stefan C Müller; Jörg Ellinger
Journal:  World J Urol       Date:  2018-02-28       Impact factor: 4.226

2.  Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series.

Authors:  Petra Anheuser; Arlo Radtke; Christian Wülfing; Jennifer Kranz; Gazanfer Belge; Klaus-Peter Dieckmann
Journal:  Urol Int       Date:  2017-06-07       Impact factor: 2.089

Review 3.  DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.

Authors:  Javier C Angulo; Jose I López; Santiago Ropero
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

4.  The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma.

Authors:  Jörg Ellinger; Jahedul Alam; Jannik Rothenburg; Mario Deng; Doris Schmidt; Isabella Syring; Herdis Miersch; Sven Perner; Stefan C Müller
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

5.  The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.

Authors:  Arlo Radtke; Finja Hennig; Raphael Ikogho; Johannes Hammel; Petra Anheuser; Christian Wülfing; Gazanfer Belge; Klaus-Peter Dieckmann
Journal:  Urol Int       Date:  2018-04-26       Impact factor: 2.089

Review 6.  The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Authors:  Javier C Angulo; Claudia Manini; Jose I López; Angel Pueyo; Begoña Colás; Santiago Ropero
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

7.  Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling.

Authors:  Mario Deng; Jasmine J Blondeau; Doris Schmidt; Sven Perner; Stefan C Müller; Jörg Ellinger
Journal:  Genom Data       Date:  2015-06-14

Review 8.  Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?

Authors:  Yong-June Kim; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2016-05-25

9.  PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.

Authors:  Emily Eva Holmes; Diane Goltz; Glen Kristiansen; Dimo Dietrich; Verena Sailer; Maria Jung; Sebastian Meller; Barbara Uhl; Jörn Dietrich; Magda Röhler; Jörg Ellinger
Journal:  Clin Epigenetics       Date:  2016-09-26       Impact factor: 6.551

10.  Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.

Authors:  Aleksandra Majchrzak-Celińska; Marta Słocińska; Anna-Maria Barciszewska; Stanisław Nowak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2015-09-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.